minutes following the depletion of blood flow, neurons and glial cells undergo apoptosis and necrosis, resulting in the formation of a cavity or infarct (Barkho and Zhao, 2011) . The cellular and tissue events that follow the onset of a stroke can be categorized into three phases: acute, subacute, and chronic (Heiss, 2012) .
The acute phase of stroke is characterized by rapid cell death, breakdown of the BBB, and infiltration of immune cells into the infarct. Hypoxia and the resulting energy deficit triggers a cascade of cell necrosis to form a infarct (Heiss, 2012; Xing et al., 2012) . Cellular excitotoxicity occurs as glutamate is released by dying neurons into the extracellular matrix (ECM) and reuptake is inhibited, resulting in high intracellular calcium concentrations. By 6 h poststroke, the majority of cell death has occurred (Heiss, 2012; Hossmann, 2012) . However, in the hours and days after a stroke there is continued cell death and impaired function in the area surrounding the infarct core, known as the peri-infarct. The peri-infarct contains cells that are impaired but can be potentially restored using therapeutic strategies (Touzani et al., 2001; Brouns and De Deyn, 2009 ).
In the subacute phase, waves of neuronal depolarization trigger further cell injury, caspase-mediated cell apoptosis and cell necrosis, which propagate from the ischemic core into the periinfarct (Velier et al., 1999) . Several molecular cascades contributing to cell death are initiated at this time, including free radical production, excitotoxicity, release of cytokines, and infiltration of macrophages and microglia causing inflammation and gliosis (Besancon et al., 2008; Barkho and Zhao, 2011) .
The last phase of a stroke is the delayed injury or chronic phase, occurring in the weeks following the initial occlusion (Heiss, 2012; Kanekar et al., 2012) . In this phase, there is widespread edema and activation of proteases and cytokines. Oxidative stress activates matrix metalloproteinases (MMPs), which disrupt tight junctions between cells and the basal lamina, and lead to a secondary breakdown of the BBB. Breakdown of the BBB in turn causes leakage of plasma, red blood cells, and infiltration of immune cells into the brain parenchyma (Brouns and De Deyn, 2009; Heiss, 2012) . Once in the brain, neutrophils and other leukocytes release proinflammatory factors, initiating a secondary wave of inflammation (Doyle et al., 2008; Brouns and De Deyn, 2009 ). There are also changes to the brain ECM that occur over time following stroke. As the basement membrane around blood vessels is degraded, collagen IV and laminin are reduced, and fibrinogen is deposited and converted to fibrin (Baeten and Akassoglou, 2011) . High-molecular-weight hyaluronan (HA) is deposited in the interstitial ECM and contributes to chondroitin sulfate proteoglycan (CSPG)-mediated restriction in plasticity and regrowth of axons . These changes can persist in the stroke infarct, and although the majority of tissue loss occurs early in the injury process, it has been shown in humans that gradual tissue loss can continue years after the initial stroke (Seghier et al., 2014) .
Current Clinical Treatments
Despite the high prevalence of stroke in North America, clinical therapies remain limited. The only FDA-approved treatment for ischemic stroke is tissue plasminogen activator (tPA), which activates plasminogen by catalyzing its conversion into plasmin, improving the outcome in ischemic stroke when administered up to 4.5 h following stroke (Stemer and Lyden, 2010) . Due to the narrow therapeutic window and risk of bleeding associated with tPA, only 3-6% of stroke patients are eligible for tPA administration (de Los Ríos la Rosa et al., 2012 ). An endovascular thrombectomy can be performed as a complement to tPA for larger vessel occlusions, but this strategy is also time-dependent (Meretoja et al., 2017) . Rehabilitation to regain function and encourage remodeling of the neural circuitry is also utilized following a stroke. Low-intensity training begins around 72 h after a stroke, followed by additional rehabilitation programs for up to 2 months poststroke (Winstein et al., 2016) . While many of the aforementioned therapies are successful, they do not promote sufficient regeneration of brain tissue to completely restore function to the brain.
Barriers to Regeneration

Blood-Brain Barrier
The BBB serves as a gatekeeper between the brain and circulating blood. The three main components of the BBB (endothelial cells, astrocytic end-feet, and pericytes) interact to form and maintain the tight junctions between endothelial cells which permit the diffusion of dissolved gases such as O2 but limit the transport of large molecules (Ballabh et al., 2004) . Following a stroke there is breakdown of the BBB leading to a lack of vascular support, infiltration of immune cells, and ultimately the formation of a cavity (Brouns and De Deyn, 2009 ). The loss of BBB integrity also limits the use of tPA due to the risk of causing a lethal hemorrhage in a blood vessel (Cheng et al., 2014) . After two waves of hyperpermeability, the first at 4-6 h and a second delayed permeability at 24-72 h (Kuroiwa et al., 1985; Krueger et al., 2013) , the BBB is gradually reestablished.
Reactive Astrocytes
Injury to the central nervous system (CNS) activates quiescent astrocytes, which undergo morphological changes to become reactive in the peri-infarct region as early as one day after stroke (Duggan et al., 2009; Barreto et al., 2011) , forming a physical and chemical barrier, known as the glial scar (Yasuda et al., 2004) . Reactive astrocytes and pericytes secrete proteoglycans, such as CSPGs, that inhibit axonal outgrowth, making their degradation a target for regenerative strategies (Fawcett and Asher, 1999; Zhang and Chopp, 2009) . Perineuronal nets, a normal component of the brain ECM, also inhibit axon regeneration (Liu et al., 2006) . However, reactive astrocytes can also play a positive role following stroke, isolating the injury site to prevent the spread of degeneration into healthy tissue, and secreting many growth-promoting proteins that can stimulate axonal sprouting Liu et al., 2014) . Since the sequence of release of both growth inhibiting and growth promoting molecules by endogenous reactive astrocytes is spatiotemporally coordinated, designing a strategy that targets astrocytes at the optimal time for therapeutic results is challenging.
Endogenous Response
Following a stroke, a considerable amount of circuit remapping takes place in both animal models (Winship and Murphy, 2008) and humans (Dancause et al., 2005) . This includes local axonal sprouting and remodeling in areas adjacent to the injury, as well as larger-scale hyperactivation of contralateral motor pathways (Tombari et al., 2004; Dancause et al., 2005) . This rewiring can serve as a compensatory mechanism to redirect functional pathways of the brain but is often insufficient to induce meaningful recovery (Winhuisen et al., 2005) .
It has been demonstrated in both rodents and humans that the brain attempts to replace lost cells through the stimulation of endogenous neural stem and progenitor cells (NSPCs) found in the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus (Morshead et al., 1994; Chiasson et al., 1999; Arvidsson et al., 2002; Yamashita et al., 2006; Minger et al., 2007) . The cells of the SVZ normally function to continually replace neurons of the olfactory bulb by migrating along the rostral migratory stream, but newly-born neuroblasts will be redirected to areas of ischemia in the striatum and cortex following injury (Pencea et al., 2001; Bedard and Parent, 2004; Kernie and Parent, 2010) . In animal models, the time of NSPC activation will vary depending on the type and size of injury, from 5 to 7 days posthypoxic/ischemic injury (Ikeda et al., 2005 ) and 2 and 6 weeks after middle cerebral artery occlusion injury . Due to the presence of cytotoxic factors and a lack of supportive ECM, the majority of NSPCs from the SVZ do not survive past 2 weeks (Arvidsson et al., 2002; Parent et al., 2002; Guerra-Crespo et al., 2012) and their ultimate contribution to regeneration is suggested to be minimal (Wernig et al., 2004; Bithell and Williams, 2005; Bliss et al., 2010; Kernie and Parent, 2010) . The cells of the SGZ, thought to be primarily neural progenitor cells (NPCs) (Nakatomi et al., 2002) , actively regenerate neurons in the granular layer of the adult hippocampus and are activated following an ischemic insult (Lindvall and Kokaia, 2010) . While there is evidence of neurogenesis in the hippocampus after global ischemia, the cells in the SGZ do not change their normal migratory pathway following injury (Wiltrout et al., 2007) , limiting their therapeutic potential beyond hippocampal injury.
Biomaterials for Brain Repair
The goal of regenerative medicine therapies after stroke is to increase the amount of functional tissue available for recovery of lost neurological function. This is achievable by: (1) protecting degenerating neural cells in the peri-infarct region, (2) regenerating new tissue to replace lost neural cells using endogenous or exogenous stem cells, and (3) creating a growth-permissive environment for new neural cells and circuitry to survive and integrate into the host tissue.
Strategies for promoting repair have revolved around delivery of drugs (proteins, antibodies, and small molecules) and cells. While promising, progress has been hindered by multiple challenges. Drug therapies are severely impeded by the restriction of drug diffusion into the brain parenchyma by the BBB, rendering most systemically administered therapies ineffective. Cell transplantation is limited by poor survival after delivery, a loss of supportive ECM and vasculature in the injured brain, and difficulty achieving maturity and integration into host tissue.
Biomaterials refer to a class of materials that are tailored to provide a beneficial effect in the targeted biological system. They can be utilized in the brain as scaffolds to provide mechanical stability to the injured brain, to provide a substrate for endogenous repair, and to address challenges in drug and cell therapies. Namely, they can be used to: bypass the BBB, provide temporal control over drug delivery, localize drug and cell therapies to targeted sites, reduce the negative effects of the hostile microenvironment, increase drug stability and cell survival, provide modulatory cues to the brain, serve as scaffolds to endogenous and exogenous stem cells, and provide guidance cues for the creation of new neural circuits.
Material Properties of the Brain
The brain is one of the softest tissues in the body, with an elastic modulus reported in the range of 0.1-500 Pa in rodents (Christ et al., 2010) and 1-14 kPa in humans (Hiscox et al., 2016) . The brain has a structurally heterogeneous anisotropy with distinct regions that vary in cellular composition and stiffness. Differences in stiffness are most pronounced between the cell-body containing gray matter and axon-dense white matter (~500 Pa in the gray matter of the rat brain versus ~300 Pa in the white matter; Kruse et al., 2008; Christ et al., 2010) , but substantial variation exists even within the same anatomical structure (Elkin et al., 2007) . The anisotropy of the brain is also reflected in the inhomogeneous diffusion parameters; for example, diffusion in the corpus callosum occurs more readily in parallel with the axon bundle than perpendicular to it (Syková and Nicholson, 2008) . The structural integrity of the brain is mediated by the ECM, which consists primarily of collagen type IV, HA, fibronectin, laminin, and proteoglycans such as CSPGs Medberry et al., 2013) . These molecules may be subdivided into three compartments with differing function: (1) the basement membrane that binds the CNS parenchyma and the vasculature, composed of collagen, laminin, fibronectin, and proteoglycans; (2) perineuronal nets that surround neuronal cell bodies, dendrites, and synapses, made primarily of CSPGs; and (3) the interstitial matrix that contains a network of molecules loosely bound to the basement membrane or perineuronal nets, consisting of proteoglycans, HA, and small amounts of collagen, elastin, laminin, and fibronectin . The composition of the brain ECM is important in the injury response; whilst scar tissue in most regions of the body (i.e., skin, heart, muscle) is typically stiffer than the surrounding healthy tissue, the glial scar is actually softer than healthy tissue. This may be partly due to the lack of fibrous collagen type I in the brain (Moeendarbary et al., 2017) .
Design Criteria for Brain Biomaterials
The delicate nature of brain tissue and the confined space of the skull imposes a unique set of design criteria for biomaterial use in the brain. The criteria for the material depend on the type of therapy but some common features emerge. The material should be biocompatible with brain tissue, which is more sensitive to mechanical and environmental stresses than other tissues (Saxena and Caroni, 2011) . For maximum biocompatibility, the mechanical properties of the material should be similar to those of brain tissue, as stiffer materials lead to increased gliosis and worsened outcomes, whereas materials softer than the host tissue lead to poor material stability at the implant site (Moshayedi et al., 2016; Spencer et al., 2017) . Due to the confined space of the skull the material must also be minimally swelling to avoid compressing the brain tissue and increasing intracranial pressure. Injectable and shape-adaptable materials are favored over stiff implants because they require less invasive surgical procedures and can conform to heterogeneous spaces. The material must be degradable and resorbable as it has been demonstrated that long-term or non-biodegradable implants, such as those made from silicone, leads to chronic inflammation, scarring, and neuron death (Biran et al., 2005) . Additionally, the degradation products must also be non-cytotoxic. The immunogenicity of the material has a significant impact on its biocompatibility. Although some inflammation is inevitable, this response can be reduced by choices in material design, such as having physical properties similar to native brain tissue (i.e., low modulus and elastic in nature) and low interfacial tension with biological fluids to minimize immune cell adhesion.
The intended use of the material will determine the importance of its properties. For drug delivery, the ability to control drug release is important for regenerative therapies and is largely dependent on material stability, drug solubility, and tissue penetration. For protein therapeutics the ability to shield against enzymatic degradation, especially in the acutely injured brain, is crucial. Yet, some materials or chemistries necessary for controlled drug release are incompatible with cell delivery due to degradation by-products or harsh fabrication conditions (Bible et al., 2012; Pakulska et al., 2013) . For cell delivery, the material must be cytocompatible, able to promote cell adhesion to prevent anoikis, able to provide good cell distribution in order to prevent cell aggregation (often observed with transplants in saline; Ballios et al., 2015) , and degradable. Topographical features, bioactive ligands, or drugs incorporated into the material can be used to guide cell behavior and fate. Finding a material with all the desired properties is challenging, thus requiring the mechanical and chemical properties to be tuned.
Types of Biomaterials Used in the Brain
Biomaterials can be produced from both natural and synthetic materials. Natural materials are derived from ECM components (e.g., HA, collagen, fibrin, laminin, heparin, peptides, and proteins) or from xenobiotic sources [e.g., alginate, chitosan, Matrigel™, silk, methylcellulose (MC)]. Naturally derived polymers are advantageous over synthetic polymers because they are made of components of the ECM or have properties similar to the ECM and are therefore less likely to stimulate an immune response (Nair and Laurencin, 2007) . Synthetic biomaterials for the brain are commonly made of polyethylene glycol (PEG), poly(d,l-lactic acid), polyglycolic acid (PGA), poly(d,l-lactic acid co-glycolic acid) (PLGA), poly(d-lysine), poly(sebacic acid) (PSA), and polycaprolactone (PCL) (Drury and Mooney, 2003; Hoffman, 2012) . Synthetic polymers are easier to tune and possess superior in vivo stability. Though they lack innate ECM components necessary for cell survival (such as adhesive ligands to prevent anoikis), they can be functionalized with bioactive ligands (Hoffman, 2012) . Biomaterials used in the brain can take on the form of injectable hydrogels, nano-and microparticles, and electrospun fibers.
Hydrogels are of particular interest as scaffolds for tissue engineering and drug delivery because they are able to form ECM-mimetic architectures. They are polymer networks crosslinked via chemical bonds or physical interactions and are primarily composed of water. Their porous and shape adaptable nature is effective for filling the stroke cavity and allows diffusion of oxygen, nutrients, and drugs required by transplanted and host cells (Drury and Mooney, 2003) . They can often be tuned to match the mechanical properties of the brain (Tyler, 2012) . Hydrogel stability is dependent, in part, on the number of the crosslinks formed; generally, physically crosslinked gels are less stable than chemically crosslinked gels, but the chemistry required for crosslinking can be detrimental to encapsulated proteins and cells, and, in some cases, the host tissue (Lee and Mooney, 2001 ). The crosslinking method also affects the rheological properties of the gel; in situ crosslinking is preferred as it allows the gel to be injected and conform to the space (Stabenfeldt et al., 2006) . Ultraviolet crosslinking can be used to chemically crosslink gels in situ, but this method has not been extensively used in the brain due to limited UV light penetration. In addition to taking advantage of their innate properties, hydrogels can be modified with customizable factors such as proteins or peptides using a number of methods, including: blending, adsorption, electrostatic interaction, chemical modification such as Schiff base reaction (Stabenfeldt et al., 2006) , Diels-Alder click chemistry (Nimmo and Shoichet, 2011) , covalent modifications (Tam et al., 2012) , and/or affinity-based binding (Vulic and Shoichet, 2014) . These modifications promote host interactions, support cell transplantation and control drug release.
Other polymeric biomaterials have been used extensively in drug delivery and tissue engineering as well; namely, particles and electrospun fibers. Particles are typically used for drug delivery and range in size from hundreds of nanometers to hundreds of micrometers (Soppimath et al., 2001; Taluja et al., 2007) . Synthetic polymers are the most widely used material for forming particles. Block copolymers of PLGA are widely used in the field of controlled drug delivery because they are one of the few biodegradable polymers approved for clinical use by the FDA (Langer, 1990; Cohen-Sela et al., 2009) . The degradation rate of polymeric particles is typically tuned by varying the particle size and composition. A common concern with PLGA is acidification of the local environment due to its acidic degradation products, potentially causing further cellular and tissue damage; however, this is a concern mostly for larger polymeric implants vs. nano/ micro-particles where the acidic products can diffuse away. Particles made of natural materials, such as heparin (Hettiaratchi et al., 2014) and chitosan (Mo et al., 2010) , avoid this issue but are less commonly used, in part due to their limited tunability. Synthetic material-derived electrospun scaffolds are attractive because their nanofibrous structure can recapitulate the microstructure of neural networks and can guide axons and neurites topographically (Schnell et al., 2007; Nisbet et al., 2009) . Cell migration into these scaffolds is limited, but may be enhanced by inclusion of electrospun fibers in hydrogels, resulting in a cellpermissive scaffold that retains the biomimetic microstructure (Bosworth et al., 2013 (Pardridge, 2012) . The small fraction of drugs that cross the BBB are often exported by surface transporters on the BBB, such as G-protein-coupled receptors (Misra et al., 2003) . Large systemic doses can increase drug diffusion across the BBB but many compounds carry risks of systemic toxicity. Modifications to drugs and carrier-mediated transport across the BBB (Pardridge, 2003) may improve delivery but still expose the body to non-specific effects of the drug and require large doses due to systemic dilution. BBB breakdown after stroke does increase diffusion into the brain parenchyma, but is limited to the infarcted tissue and a narrow window of opportunity for administration; with reestablishment of the BBB, systemic delivery of therapeutics is again limited (Pardridge, 2012) . Similarly, methods to disrupt the BBB, such as hypotonic solutions or focused ultrasound (Vykhodtseva et al., 2008) , are non-specific and render the CNS vulnerable to circulating pathogens, making them unsuitable for sustained drug therapies. Circumventing the BBB with local drug delivery increases the amount of drug at the target site, reducing systemic exposure and the risk of systemic toxicity. Clinical methods administer drugs by intracerebroventricular or intracortical infusion through a catheter (the Ommaya reservoir; Mead et al., 2014) . These routes are fraught with issues, as fluid injection into the small ventricular spaces increases intracranial pressure and has been associated with hemorrhage, leakage of cerebrospinal fluid (CSF), and infection (Misra et al., 2003; Mead et al., 2014) . Additionally, there is evidence that administration of drug into the CSF does not necessarily increase drug transport into the brain parenchyma (Pardridge, 2011) . Convection enhanced delivery has been tested as a solution to increase drug distribution into the brain parenchyma by using a pressure gradient to drive convective transport through the interstitial spaces in the brain, achieving tissue penetration up to several centimeters vs. the millimeter range observed with diffusive transport (Mehta et al., 2017) . However, this method is only conducive to bolus injections and cannot provide sustained delivery. Additionally, problems of increased intracranial pressure, damage to the infusion site, and damage due to needle insertion into brain tissue are still present.
Biomaterials that can be used for sustained local drug delivery to the brain in a minimally invasive manner have become important for drug therapy because they address many of the challenges surrounding delivery. Here, we discuss the use of biomaterials to improve local drug delivery and control drug release. We focus on the advances that have been made using biomaterials and drugs to: (1) protect cells, (2) stimulate regeneration, and (3) promote plasticity ( Table 1) . The therapeutic effects of biomaterials on host tissue will also be discussed.
Local Drug Delivery to the Brain
Biomaterial-based local drug delivery systems can overcome the limitations of traditional catheter-based systems. Drug diffusion in the brain is affected by the size (38-64 nm between cells) and tortuosity (λ = ~1.7 in uninjured brain, ~2.1 in injured brain) of the extracellular space, interactions with cellular receptors, and affinities for charged moieties in the ECM (Thorne et al., 2008) . Brain injury will change these parameters and reduce the effective diffusivity, thereby making it difficult to achieve therapeutic concentrations at distances greater than several centimeters. Tissue penetration-the distance the drug is found from the source at detectable concentrations-can be enhanced by increasing the drug concentration at the source, reducing binding to the ECM, or decreasing elimination and degradation. Providing a sustained source of drugs would maintain a higher driving force for diffusion and increase penetration. Shielding the protein from extracellular degradation can increase effective diffusion, as was shown by the threefold increased tissue penetration after PEGylating epidermal growth factor (EGF) (Wang et al., 2011b) . In some cases, it is important to control the spatial distribution of the molecule, not just the tissue penetration, as this can profoundly affect physiological response. For example, mice expressing vascular endothelial growth factor-A (VEGF-A) isoforms with high ECM binding affinity, with steep concentration gradients and low tissue penetration, exhibited thin, highly branched blood vessels while non-ECM binding VEGF isoforms, with shallow concentration gradients and higher concentrations further away from the source, exhibited wide, leaky vessels (Ruhrberg et al., 2002) .
Delivery can take two forms: intracranial delivery and epicortical delivery (Figure 1) . Intracranial delivery into the stroke infarct limits damage to healthy tissue. As the peri-infarct region is often the site of many protective and regenerative therapies (Carmichael et al., 2005) , this also positions the drug closer to the site of action and reduces the diffusion distance, ensuring therapeutically relevant concentrations are reached. One limitation of intracranial delivery is the limited range of drug transport by diffusion (in the range of millimeters) that is adequate for animal models but may not scale to the larger human brain. However, postinjury plasticity is often mediated by the peri-infarct tissue located millimeters to tens of millimeters from the infarct boundary zone (Nudo et al., 1996; Luft et al., 2004; Carmichael et al., 2005; Brown et al., 2009 ). Thus, in most cases, the diffusive range seen in animal models may be translatable to humans.
Epi-cortical delivery has been explored as a minimally invasive method of drug delivery to the brain (Cooke et al., 2011; Tuladhar et al., 2015) . With this method a drug-loaded scaffold is implanted onto the surface of the brain, thus avoiding tissue damage caused by needle insertion as is seen with intracranial and convection-enhanced delivery. In the mouse and rat, proteins and drugs delivered epi-cortically can diffuse through the cortex and reach the subcortical NSPCs located in the lateral ventricles. A drawback of this approach is the larger diffusion distance required to reach the site of action. Although this method may not be amenable to targeting the subcortical ventricles in the larger human brain due to limits of diffusive transport, treatments targeting the thin (1-5 mm) cortical regions of the human brain (Fischl and Dale, 2000) may be amenable to epi-cortical delivery. 
BDNF + GDNF BDNF and GDNF were separately encapsulated in PLGA particles to achieve different release rates and loaded into a biodegradable PEG hydrogel strand, injected into the substantia nigra and striatum of uninjured female SD rats Achieved slow and long-term release of BDNF for over 8 weeks, and faster release of GDNF over 28 days. Swelling was minimal. Slightly elevated astrogliosis but reduced microgliosis Lampe et al. (2011) NT-3 Chitosan microparticles loaded with NT-3 by adsorption onto particle surface and suspended in a collagen-1 solution, injected into infarct in hippocampal TBI model
Chitosan carrier reduced gliosis and slightly increased axon regeneration. NT-3 increased axon regeneration into the injury site. Recovery in water maze task with chitosan carrier group; no further recovery with NT-3 
Controlling Drug Release
Protective and regenerative therapies require sustained drug exposure to be efficacious (Wieloch and Nikolich, 2006) . In the absence of control mechanisms, drugs given by bolus injection are cleared in several hours and drug release from a hydrogel depot is typically complete within 2-4 days. The release window may be extended to several weeks or months by retarding diffusion out of the depot through encapsulation or immobilization in the matrix (Soppimath et al., 2001) or by affinity interactions with the matrix (Vulic and Shoichet, 2014) . Polymeric micro-and nano-particle systems control release by encapsulating drugs within a biodegradable polymer matrix. Drug release from bulk-degrading polymers, such as PLGA, involves multiple mechanisms (Han et al., 2016) . The initial release, FiGURe 1 | Biomaterials can be used to delivery drugs by either (A) intracranial injection into space provided by the stroke injury or (B) epi-cortical implant on the surface of the brain to prevent any further damage due to injection. Reprinted from Tuladhar et al. (2015) with permission from Elsevier.
termed the burst phase, occurs from the surface bound drug and usually takes place within hours barring any interactions between drug and material. The next release phase occurs by diffusion of the drug through pores formed in the particle as the polymer degrades or swells. Finally, bulk degradation and polymer erosion results in the release of any remaining drug. Polymeric particles for drug release can range from several hundred nanometers to approximately 100 μm (Soppimath et al., 2001; Taluja et al., 2007) . Microparticles made from natural or ECM components, such as heparin and chitosan (Agnihotri et al., 2004; Lin et al., 2009) , have been used but they lack the tunability of common synthetic materials such as poly(esters) (e.g., PLGA; Mohammadi-Samani and Taghipour, 2015) and poly(anhydrides) (e.g., PSA) (Kumar et al., 2002) . The release period from PLGA particles can be tuned from 1 to 2 weeks to several months by varying the relative ratios of lactic acid and glycolic acid monomers, the copolymer chain length, the molecular weight of PLGA, or the terminal functional groups (Pollauf et al., 2005) . Multiple drugs can be incorporated into the same particle and the use of slow and fast degrading PLGA variants allows for precise temporal release that better mimics signaling patterns found in vivo (Richardson et al., 2001; Lampe et al., 2011; Brudno et al., 2013) . In addition, double-walled particles can be made using a mix of two polymers (Pekarek et al., 1994) . Here, a drug-loaded core is coated with a drug-free shell; using a polyanhydride for the shell will result in a delayed release, where the surface eroding shell degrades before the drug is released from the core. Combining a classical PLGA particle with this double-walled particle allowed the sequential release of EGF followed a week later by erythropoietin (EPO) , mimicking the release paradigm of more invasive osmotic mini-pumps and cannulas used to stimulate endogenous brain NSPCs (Kolb et al., 2007) but in a minimally invasive manner.
Drugs can also be covalently immobilized within hydrogel matrices. The drug can act on cells at the hydrogel-tissue interface and on infiltrating cells. Immobilized proteins can cause a drastically different tissue response compared to soluble protein by inducing differential changes in receptor internalization and trafficking (Clegg and Mac Gabhann, 2015) and in downstream signaling pathways (Chen et al., 2010b) . Proteins can be immobilized in a hydrogel using chemical conjugation (Ehrbar et al., 2007) . Drug release is dictated by the rate of hydrogel degradation, which can be tuned to be environmentally responsive to enzymes [e.g., MMPs (Purcell et al., 2014) ] secreted by, for example, NSPCs (Barkho et al., 2008) or endothelial cells (Rundhaug, 2005) .
Naturally occurring affinity interactions between proteins and the ECM have been employed in biomaterials through natural or functionalized binding sites that control release through transient hydrophobic and electrostatic interactions. A key advantage of these systems is that the harsh encapsulation process necessary for particle systems is avoided, preserving protein function and stability. Release can be tuned by modifying the strength of the affinity interaction, the concentration of binding ligand, and the rate of dissociation (Vulic and Shoichet, 2014) . Heparin is the most popular platform for affinity release because it has a natural affinity for a number of heparin binding proteins relevant for regeneration [e.g., fibroblast growth factor (FGF), VEGF, insulin growth factor (IGF), platelet-derived growth factor, stromalderived factor (SDF), and bone morphogenic proteins (BMPs); Capila and Linhardt, 2002] . It has been used to form hydrogels and particles or to functionalize other materials (SakiyamaElbert, 2014) . To overcome the lack of specificity of heparin interactions, which is problematic in the heparin binding protein rich environment found in vivo, a variety of solutions have been pursued and include: heparan sulfate variants, selectively desulfated heparin, and heparin fractions with protein-specific affinity . A drawback to this approach is the limited ability to tune the strength of the heparin-protein interaction and the inherent limitation to heparin-binding proteins. The creation of fusion proteins with SH3-domains that interact with SH3-binding peptides bound to a gel enables specific affinity release strategies for a wider range of proteins (Vulic and Shoichet, 2012) . This strategy allows for the controlled release of many proteins, including those too delicate for encapsulation and lacking affinity for heparin, as was demonstrated with the enzyme chondroitinase ABC (ChABC) (Pakulska et al., 2013) . Multiple drugs can be released from the same vehicle with this system using the same material; however, the release rate of two or more drugs cannot be independently tuned. If the system is reversed whereby SH3-binding peptides are coexpressed with proteins and SH3 covalently bound to the hydrogel, controlled release of multiple proteins with independent release rates will be dictated by the unique SH3-binding peptide on each fusion protein (Delplace et al., 2016) . Advances in computational design of protein-protein interactions and phage display libraries will increase the variety of binding interactions available for affinity release strategies, increasing their utility (Pakulska et al., 2016b) . Recently, innovative work has used electrostatic interactions to control drug release from PLGA particles without the need for encapsulation (Pakulska et al., 2016a) . The key advantage to this approach is the ability to control release of many relevant molecules [e.g., SDF, neurotrophin-3 (NT-3), and brain-derived neurotrophic factor (BDNF)] using the same nanoparticle, avoiding the harsh encapsulation process that often denatures proteins and reduces drug loading. Release can be tuned simply by varying nanoparticle size, concentration, and degradation rate. One limitation to the system is that the anionic particle can only interact with positively charged proteins. Modifying the particle with a positively charged component, such as chitosan, may allow electrostatic control of negatively charged proteins (Kumar et al., 2004) . Laponite, derived from clay, can electrostatically control release of negatively charged proteins (Koshy et al., 2018) , but the non-biodegradable silica degradation products make the platform incompatible with the brain.
Protecting Neural Cells
Neuroprotective strategies for stroke have been investigated to save existing cells and neural circuits by either (a) directly reducing cell death, demyelination, and axon death in the stroke peri-infarct or (b) mitigating secondary damage caused by excitotoxicity, inflammation, and oxidative stress. However, the utility of this approach was brought into question when it was noted, in 2006, that although 1,026 neuroprotective agents had been identified and tested in preclinical studies (O'Collins et al., 2006) and almost 200 had reached various stages of clinical trial, nearly all had failed to demonstrate clinical efficacy. tPa, first tested in 1988, was the only exception (Stroke trials registry page, http://www. strokecenter.org/trials) . Discrepancies between preclinical and clinical studies (e.g., population age, scope of injury, and primary endpoint) likely contribute to the clinical failures . Despite the lack of clinical translation, neuroprotective strategies are still actively being investigated and evaluated using more targeted approaches based on mechanistic studies (Rajah and Ding, 2017) .
The advent of biomaterials may give new life to neuroprotective molecules that have previously failed due to poor BBB penetration and low concentrations in poorly perfused ischemic regions. VEGF released from an alginate hydrogel provided exposure for 1 week, compared to <10 h from a bolus injection, resulting in reduced stroke infarct size and neurological deficit (Emerich et al., 2010) . The materials themselves offer some neuroprotection by providing structural support, attenuating gliosis and inflammation, and reducing cavitation. Bioactive materials, like HA, reduce inflammation through the CD44 receptor by inhibiting leukocyte migration and inflammation (Forrester and Wilkinson, 1981; Cooper et al., 2008) , resulting in reduced microglial activation (Wang et al., 2012b) and stroke infarct volume (Hou et al., 2005; Austin et al., 2012; Wang et al., 2013; Tuladhar et al., 2015) .
Recently, the effect of hydrogel structure alone on tissue repair was investigated by comparing a micro-porous HA hydrogel, synthesized by crosslinking HA-RGD microbeads in situ, to a nano-porous hydrogel while keeping the bulk moduli and biochemical signaling the same (Figures 2A-E) (Nih et al., 2017) . Both structures reduced the thickness of the glial scar and degree of macrophage activation in the peri-infarct region; however, the magnitude of this effect was greatly increased in the microporous gel. Additionally, the microporous gel reduced macrophage activity within the stroke infarct. To have even greater benefit, neuroprotective drugs may be delivered from a microporous gel, as has been shown with gelatin microspheres to deliver anti-inflammatory (Jin et al., 2011b) or proregenerative molecules.
Stimulating endogenous Stem Cells
Stimulating endogenous NSPC populations in the brain requires therapeutics to influence their proliferation, survival, migration, and differentiation (Wiltrout et al., 2007; Guerra-Crespo et al., 2012; Wang et al., 2012a ). An array of growth factors and cytokines has been found to be important in endogenous NSPC signaling. Often, these factors have multiple and overlapping effects on the NSPCs. Many of the factors investigated for endogenous NSPC stimulation are naturally upregulated within hours to days after stroke as part of the injury response, but this is transient and in the majority of cases returns to basal levels within a week. These molecules include growth factors and cytokines to stimulate: proliferation [e.g., EGF, FGF2, VEGF, human chorionic gonadotrophin (hCG), hepatocyte growth factor (HGF), BDNF, IGF1], survival [e.g., VEGF, EGF, BDNF, glial-derived neurotrophic factor (GDNF)], migration (e.g., SDF1a, VEGF, BDNF), and differentiation (e.g., BDNF, EPO, GDNF, BMP4, HGF). The only drugs that have been tested clinically are hCG and EPO, and while preclinical results demonstrated increased endogenous NSPC mobilization and neuronal differentiation (Belayev et al., 2009) , the clinical trial was inconclusive (Cramer et al., 2010) . Although the clinical trial failed to demonstrate a benefit compared to saline controls, and was thus prematurely terminated, it was found in post hoc analysis that the subgroup of patients also receiving occupational therapy benefited from hCG and EPO treatment. Small molecule drugs clinically used for other therapeutic purposes have been found to stimulate NSPCs and promote recovery. Cyclosporine (CsA), a common immunosuppressant, is found to increase NSPC survival in vitro and in vivo, and to reduce stroke infarct volume Erlandsson et al., 2011; Sachewsky et al., 2014) . Metformin, a drug for diabetes, stimulates neurogenesis in the hippocampus, improving memory in injured mice (Wang et al., 2012a) ; a clinical trial is underway to evaluate its potential in treating brain injury in children (NCT02040376). Many studies have demonstrated improved outcomes when combining regenerative strategies with biomaterial delivery systems for controlled release of drugs. Controlled release of HGF and IGF1 from gelatin microspheres increased the number of neuronal progenitors while bolus IGF1 or HGF injections failed to stimulate the NSPCs (Nakaguchi et al., 2012) . Although controlled release may be achieved through infusion strategies, this method is deleterious to the NSPC niche and may negate any beneficial effects of delivered factors . Intracortical BDNF injections can stimulate NSPCs but requires extended exposure (Schabitz et al., 1997) . BDNF modified with a collagen binding domain increased retention in the tissue by binding to collagen in the ventricular NSPC niche, significantly stimulating NSPC proliferation and neurogenesis compared to unmodified BDNF that lacks the ability to bind to the niche (Guan et al., 2012) . Incorporating the collagen binding domain in a HA hydrogel results in drug release over multiple weeks (Cook et al., 2017) . Stroke-injured animals receiving BDNF from this hydrogel recovered motor function accompanied by NSPC proliferation and neurogenesis. However, because BDNF can exert recovery through a variety of mechanisms (e.g., synaptogenesis and angiogenesis) it is unclear how recovery was mediated.
Epi-cortical EGF and EPO delivery with HAMC, a hydrogel blend of HA and methycellulose, increased NSPC proliferation and neurogenesis, but the short release window (2 days) may be insufficient for substantial regeneration and long-term recovery (Cooke et al., 2011; Wang et al., 2012b) . Previous work with EGF and EPO demonstrated that sequential delivery of the two compounds into the ventricle with a cannula, for 7 days each, produced significant tissue regeneration and motor recovery (Kolb et al., 2007) . Therefore, to mimic this release profile a composite delivery system using HAMC, PLGA nanoparticles, and doublewalled PLGA/polyanhydride microparticles was used to achieve sequential and extended release of EGF and EPO . This bioengineered strategy increased NSPC proliferation and survival compared to cannula delivery in a mouse model of stroke. This appears to be partly caused by reduced glial scarring and microglial activation by the vehicle, likely mediated by the HA component, and increased cell death in the SVZ due to cannula insertion. Controlled release of individual drugs was not tested, so it is unclear whether a synergistic effect of EGF and EPO was necessary for the effects reported. While a clear tissue benefit was seen, it is unknown whether this was accompanied by behavioral recovery. Epi-cortical delivery has also been tested in the larger rat model with cyclosporine, demonstrating sufficient tissue penetration to stimulate proliferating endogenous NSPCs (Tuladhar et al., 2015) .
In a few cases, the material alone has had an impact on host NSPCs. The aforementioned micro-porous HA-RGD hydrogels stimulated NSPC proliferation in the SVZ-an effect not seen with nanoporous gels (Figures 2A,F-H) (Nih et al., 2017) . While neuroblasts were reported to have migrated into the gels, it is unclear how the material stimulated NSPC proliferation. Aligned PCL nanofibers were used to promote NSPC migration into the injury site; however, long-term neuroblast survival required inclusion of a BDNF-mimetic peptide (Fon et al., 2014) .
Promoting Plasticity
Neuroplasticity is defined as the brain's ability to modify its neural circuitry and is necessary to restore function (Dimyan and Cohen, 2011) . Spared or newly generated tissue must be integrated into the uninjured neural network and adapt to functional demands. This requires the creation of new connections, modification of existing neural circuitry, and removal of plasticity inhibiting elements. Agonists of Trk receptors are involved in neuronal plasticity (Thoenen, 1995) and the two factors most investigated for stimulating this mechanism are NT-3 and BDNF. NT-3 has a key role in the development and repair of motor circuits (Patel et al., 2003; Chen et al., 2006 ) and delivery to stroke-injured animals increases axonal sprouting (Duricki et al., 2016) . Chitosan particles suspended in a collagen 1 solution have been used to deliver NT-3 to the hippocampus in a traumatic brain injury (TBI) model (Mo et al., 2010) . Interestingly, the chitosan particles alone resulted in increased axonal sprouting compared to injuryonly groups, while NT-3 further increased the amount of axon regeneration. However, behavioral recovery was significant with the chitosan vehicle alone and, surprisingly, the addition of NT-3 did not increase this recovery. This lack of additional recovery with NT-3 may not necessarily indicate that NT-3 is ineffective; rather, the axonal sprouting seen with chitosan may be sufficient for behavioral recovery and any additional improvement requires other mechanisms. In contrast, in a rat spinal cord injury model, a HAMC and PLGA-based NT-3 delivery system induced both axonal sprouting and motor recovery (Elliott Donaghue et al., 2015) . The difference in outcomes may be due to differing etiologies in the two CNS compartments and different requirements for recovery.
Modifying existing neural circuits requires synaptic plasticity at axon-dendrite terminals to strengthen or weaken existing connections and appears to be mediated by BDNF. Delivering BDNF improves motor recovery (Müller et al., 2008) while blocking BDNF signaling reduces any recovery seen with plasticity-dependent rehabilitative training (Ploughman et al., 2009) . Although BDNF expression is upregulated after stroke injury this effect is transient and is reduced with age, making plasticity-based recovery paradigms difficult in chronic stroke and aged populations. While systemically delivered AMPAkine stimulated recovery in young animals, by inducing BDNF release (Clarkson et al., 2011) , recovery was dampened in aged animals (Clarkson et al., 2015) due to reduced BDNF expression in this population. Interestingly, combining the systemically administered AMPAkine with local BDNF delivery through a HA-based hydrogel modified with collagen-binding domains improved recovery in aged animals to levels comparable to young animals (Clarkson et al., 2015) . This is one of the few studies involving biomaterials that investigated mechanistic pathways mediating this process, demonstrating that BDNF delivered from the hydrogel upregulates canonical BDNF signaling pathways. The delivery system uses the affinity of BDNF for collagen to control release and increased local BDNF concentrations for at least 3 weeks postimplant (Cook et al., 2017) . Additionally, intracranial delivery of the gel to a non-human primate stroke model resulted in sufficient BDNF accumulation in the peri-infarct area (within 1-2 cm), a distance relevant for recovery in humans (Nudo et al., 1996; Luft et al., 2004) . Interestingly, the drug concentration around the implant varied depending on the direction measured, highlighting the anisotropy of the brain and its effect on diffusion. Importantly, the authors highlight that BDNF only increases the strength of existing connections and cannot overcome growth inhibitors. Thus, BDNF treatment alone may be in insufficient in cases where new connections need to be made, such as when existing connections are insufficient to support adaptive plasticity, or in chronic stroke, where glial inhibition is a significant barrier.
The adult brain ECM and glial cells express many growth inhibitory molecules that limit synaptogenesis and axonogenesis, such as the neurite outgrowth inhibitor (Nogo) (Schwab and Strittmatter, 2014) . Inhibiting the activity of these molecules, such as with an anti-NogoA antibody, enhances regeneration, plasticity, and recovery (Buchli and Schwab, 2005) . A HA hydrogel was used to deliver a Nogo66 receptor antibody in strokeinjured rats; although increased nerve fiber growth was seen, it was insufficient to produce any significant behavioral recovery (Ma et al., 2007) . Combining NogoA inhibition with a growth stimulatory molecule may produce a synergistic effect on axon growth. Controlling the release of anti-NogoA and codelivering it with NT-3 was investigated using a blend of HAMC and PLGA FiGURe 3 | Biomaterials can be used to address challenges at multiple stages of the cell transplantation paradigm. 1. Biomaterials can be used to prime cells in culture prior to injection to guide cell fate and limit death during transfer to a syringe. 2. The use of a shear thinning or crosslinked hydrogel can decrease mechanical stress that cells undergo during processing and injection. 3. Biomaterials can aid in cell retention at the injection site and increase cell survival with the addition of adhesion peptides and ECM components. 4. Long-term cell integration can be supported with a biomaterial with factors and topographical cues for cell differentiation, axon guidance, and synapse formation.
particles; increased axon density and improved motor function were achieved in a rat spinal cord injury model (Elliott . Perineuronal nets are ECM structures surrounding axon terminals that stabilize synapses in the healthy brain but inhibit new connections in the injured and adult brain (Wang and Fawcett, 2012) . ChABC has been found to increase synaptic plasticity by transiently destabilizing these perineuronal nets (Massey et al., 2006) . Biomaterial delivery systems have been developed for ChABC (Pakulska et al., 2013) , to stimulate recovery in spinal cord injury (Pakulska et al., 2017) , and can be applied to existing delivery paradigms in the brain.
CeLL DeLiveRY Goals of Cell Therapy
As an alternative to drug delivery, many strategies focus on the delivery of an exogenous source of cells to treat stroke. The aim of cell transplantation is to increase the survival of endogenous cells as well as to directly replace damaged tissue to promote regeneration. Cell types used for transplantation to the brain include adult NSCs, mesenchymal stromal cells (MSCs), embryonic stem cell (ESC)-or induced pluripotent stem cell (iPSC)-derived NPCs, and directly reprogrammed induced neural stem cells (Yamashita et al., 2017) . Early research also included undifferentiated pluripotent stem cells, however, their use has become limited due to the risk of teratoma and tumor formation (Kawai et al., 2010; Yamashita et al., 2011) . Transplanted cells have been demonstrated to promote stroke recovery in animal models through a variety of mechanisms: stimulating both endogenous NPCs and endothelial progenitor cells to migrate to ischemic sites (Bliss et al., 2010; Lindvall and Kokaia, 2011; Dailey et al., 2013) , stimulating the proliferation of neuroblasts in the SVZ (Chen et al., 2003; Jin et al., 2011a; Zhang et al., 2011) , promoting angiogenesis in the peri-infarct zone (Horie et al., 2011; Zhang et al., 2011; Oki et al., 2012) , and decreasing infarct size (Chen et al., 2010a; Gomi et al., 2012; Oki et al., 2012) . In addition to the effects on endogenous tissue, transplanted cells can integrate into the existing neural circuitry, reestablishing connections with host cells ; however, it remains unclear if these new connections contribute directly to recovery.
Although cell transplantation can stimulate stroke recovery in animal models, appreciable long-term survival of cells continues to remain elusive, with an estimated survival of only 2-8% of the initial transplant population (Nakagomi et al., 2009 ). This poor survival is attributed to cell death during the transplantation process, lack of endogenous ECM and vasculature in the stroke cavity, lack of prosurvival signals, and low rates of cell differentiation and integration (Modo et al., 2002; Kelly et al., 2004; Hicks et al., 2009) . Biomaterials are becoming an important part of the cell delivery paradigm, enhancing the success of cell transplantation through four main strategies, discussed herein, by providing: (1) a platform for in vitro predifferentiation of cells prior to transplantation; (2) a delivery vehicle to reduce acute cell death during the delivery process; (3) a scaffold for cell adhesion and survival after delivery; and (4) a platform for the codelivery of cells and factors to promote cell differentiation and integration (Figure 3) . Most biomaterials used for cell transplantation to the brain are hydrogels, and thus will be the focus of this discussion. It is also important to note that many strategies are multifaceted, involving ECM components and proteins that will enhance cell survival, direct differentiation, and/or recruit endogenous cells.
Biomaterials for Cell Therapy
Early studies of biomaterials for cell transplantation focused on the use of synthetic polymers such as PEG, a highly hydrophilic polymer that is biocompatible and non-immunogenic (Bjugstad et al., 2008; Bhattarai et al., 2010) . PEG can be combined with other synthetic polymers, such as PLGA, or with natural polymers. PEG has been used to design hydrogels for cell culture, incorporating FGF2 and type I collagen (Mahoney and Anseth, 2007) , or heparin and RGD (Freudenberg et al., 2009 ) to culture embryonic NSCs, which were both found to increase cell viability. Other synthetic polymers [PGA, PLGA, poly(d-lysine) , PCL] are used for a range of applications including: in vitro coating of polycarbonate or plastics [e.g., poly(l-lysine); Jongpaiboonkit et al., 2008] , scaffold particles for structural support for cell transplantation (e.g., PLGA; Bible et al., 2009) , electrospun nanoparticles (e.g., PCL; Horne et al., 2010) , and 3D scaffolds (e.g., PGA; Park et al., 2002) . For example, when a PGA 3D scaffold was used to deliver NSCs into the stroke-injured neonatal mouse brain and compared to cell delivery in saline, the scaffold attenuated the immune response, reduced glial scarring, allowed penetration of blood vessels, and promoted differentiation of delivered cells into neurons and glia (Park et al., 2002) . While there are advantages to synthetic biomaterials, there are also drawbacks such as biocompatibility issues with many of their acidic degradation products and their inability to interface with native cells and enzymes (Hoffman, 2012) . Natural hydrogels are favored for cell transplantation after stroke due to the similarity in mechanical properties with native brain tissue (i.e., soft consistency and elastic nature) ( Table 2) . One natural hydrogel used for cell delivery is Matrigel™, a material derived from a mouse sarcoma cell line primarily composed of laminin-1 and collagen IV and containing many adhesive molecules and growth factors that promote cell viability. Transplantation of mouse ESC-derived NPCs in Matrigel™ into the striatum resulted in a larger graft volume and increased the number of tyrosine hydroxylase-positive dopaminergic neurons (Uemura et al., 2010) . Unfortunately, as Matrigel™ is derived from a xenobiotic source, it has high batch-to-batch variability and is unsuitable for clinical use (Jin et al., 2010) . In addition, Matrigel™ gels at room temperature through hydrophobic interactions between the components, causing it to be technically challenging for cell injection. To retain the desirable properties of Matrigel™ without its drawbacks, other strategies have favored the use of ECM-based hydrogels such as HA, fibrin, and collagen as they are well-defined and tunable (Nair and Laurencin, 2007; Nih et al., 2016) .
As an alternative to isolating one individual component of the ECM to create a hydrogel, researchers have also derived a multicomponent hydrogel from decellularized natural ECM. Porcine bladder-derived ECM hydrogels promote in vitro 3D neurite extension (Medberry et al., 2013) , and when injected into the cavity of stroke-injured rat brain led to infiltration of neural progenitors and oligodendrocytes into the gel-filled space (Massensini et al., 2015; Ghuman et al., 2016) . Natural ECM hydrogels have also been derived from brain and spinal cord, and some have been electrospun with other components for in vitro culture to demonstrate neurite extension (Baiguera et al., 2014; De Waele et al., 2015) . One study comparing bladder, spinal cord, and brain ECM reported that there were differences in the chemical composition and mechanical properties between them, and that while all three were able to promote neurite formation, brain ECM promoted the longest and most numerous neurites in a neuroblastoma cell line (Medberry et al., 2013) indicating the superiority of brain-derived ECM for neuronal culture. In Vitro Cell Priming Biomaterials can be used to culture cells prior to transplantation, enhancing the success of cell therapies. It has been demonstrated that priming cells in vitro through a variety of mechanismsguiding differentiation, stimulating the secretion of factors, or exposing cells to stressful conditions-can increase their therapeutic efficacy once delivered to the brain (Rosenblum et al., 2015; Lee et al., 2017) . It has also been suggested that predifferentiating pluripotent or multipotent cells toward a neuronal lineage prior to transplantation can increase tissue and behavioral recovery (Fricker-Gates et al., 2002; Tornero et al., 2013) . Culturing adult and embryonic NPCs in 3D HA hydrogels can promote differentiation and enhance neurite outgrowth and synapse formation Hou et al., 2005; Khaing and Seidlits, 2015) . The addition of factors into HA hydrogels can enhance the desired priming effects. For example, a design of experiment approach was used by Lam et al. to optimize the concentration of adhesive peptides-RGD, IKVAV, and YIGSR-on HA hydrogels for 3D NPC survival and differentiation (Lam et al., 2015) . The authors determined that the optimal concentration of each peptide was not the often used 1:1:1 ratio, and that strategic optimization of each factor concentration can lead to enhanced survival and neurite length. Another study combined both RGD and heparin components within a HA hydrogel using click chemistry to culture hPSC-derived NPCs and differentiate them into midbrain dopaminergic neurons for transplantation (Adil et al., 2017) . The use of both factors increased cell differentiation, neurite extension, and resulted in functional neurons that could fire action potentials in vitro. When transplanted into the rat striatum these cells showed a fivefold increase in cell number compared to unencapsulated controls. Lastly, in an approach targeting cell migration, Addington et al. (2015) aimed to enhance the NSC response to in vivo SDF-1α gradients by priming the cells in culture with HA-laminin hydrogels. The authors reported that culturing NSPCs in these gels resulted in an increased response to SDF-1α gradients in vitro, with increased CXCR4 receptor expression after 48 h of culture that was dependent on the concentration of HA and laminin used. In a follow-up study, the researchers transplanted HA-laminin-primed NSPCs into intact mouse brains and reported an increase in cell migration out of the transplantation site that was dependent on the SDF-1α/CXCR4 interaction (Addington et al., 2017) .
improving Cell Delivery
The majority of intracerebral cell delivery strategies are syringebased. Necessary steps in the transplantation paradigm, such as preparation of cells for transfer from culture into a syringe, and injection of cells into the brain, can result in a substantial amount of cell death (Rossetti et al., 2016; Payne et al., 2017) . Small-bore needles are favored for cell delivery as they are minimally-invasive for the host tissue; however, they increase the mechanical disruption and shear stress that cells experience during injection (Rossetti et al., 2016) . Other variables such as time between preparation and implantation of cells, concentration of cells, needle length, rate of injection, and suspension medium all impact the survival of cells (Heng et al., 2009; Amer et al., 2015; Rossetti et al., 2016) . Although not often reported, this acute loss of cells can impact the therapeutic success of cell transplantation at the onset of delivery. The ability of biomaterials to reduce acute cell death has been tested using several hydrogel systems. The extensional shear stress that cells experience as they pass through the comparatively large diameter syringe into the smaller diameter needle can be reduced by encapsulation in a biomaterial. Amer et al. (2015) investigated the effect of the vehicle during injection on fibroblast viability using crosslinked or non-crosslinked alginate gels, as well as a high viscosity carboxymethylcellulose solution, and determined that only the crosslinked alginate hydrogel significantly increased acute viability of cells. It has been suggested that crosslinked hydrogels can undergo plug flow where the hydrogel at the interface of the syringe and needle will undergo shear thinning and this acts as a lubricant to the inner core of the gel, thus reducing the shear stress and extensional forces experienced by the cells. A crosslinked alginate hydrogel also increased viability of human umbilical vein endothelial cells and mouse NPCs immediately after injection, from 59% survival in saline to 89% in the hydrogel (Aguado et al., 2011) ; however, the authors did not test the hydrogel for long-term cell culture or in vivo viability, which could be impacted by the hydrogel crosslinking, which determines the elastic modulus and the gel stiffness (Banerjee et al., 2009) . HA also promotes iPSC-NPC viability when high concentrations of cells (i.e., 60-90k cells/μL) were injected through a needle of 28-gage or higher compared to a buffer solution (Lam et al., 2014) . Interestingly, viability can vary depending on the susceptibility of the specific cell type to damage. For example, a mature neuronal phenotype experiences more cell death with the use of a HA-MC gel than less-differentiated NPCs (Payne et al., 2017) .
A single scaffold can be used to first culture and then deliver cells into the brain, avoiding cell death due to dissociation and supporting cell survival and function both pre-and postinjection. Electrospun synthetic poly(desaminotyrosyl tyrosine ethyl ester carbonate) microfibers were used to accelerate the differentiation of human iPSCs into induced neuronal cells in vitro (Carlson et al., 2016) . Cells grown and differentiated on these fibers and transplanted into the mouse striatum survived better than dissociated cells alone. In an interesting approach, the Cullen lab devised micro-tissue engineered neural networks (microTENNs) to deliver preformed networks of axonal tracts both with and without astrocyte support (Struzyna et al., 2015; Winter et al., 2016) . These constructs consist of an outer columnar agarose shell that is filled with an ECM hydrogel, such as collagen or laminin. Cells are then either seeded at one end of the tube where they extend neurites through the construct, or are dispersed along the length of the construct and cultured to create a neural network that can then be transplanted directly into the brain. In addition, once formed, the neural network can be removed still intact from the construct for further culture or immunochemical analysis. Micro-TENNS can be inserted directly without the use of a needle into the brain and, in naïve rats, resulted in cell survival for up to 1 month, maintenance of an axonal network, and shortdistance integration into the host tissue (Struzyna et al., 2015) . Coculturing neurons along astrocyte networks within collagen hydrogel micro-columns resulted in neurites that extended along the astrocytic bundles, mimicking the glial tube of the rostral migratory stream that guides neuroblasts in vivo (Winter et al., 2016) . Although promising, one potential issue with these constructs is scaling up for humans; it is unclear how much larger the scaffolds would need to be to traverse damaged areas in the human brain, and whether this would affect insertability and cell viability. In addition, material degradation and cytocompatibility of bioresorption products require further investigation.
increasing Cell Retention and Survival
Cell Retention
Although cell delivery can be achieved via intravascular or intracerebroventricular delivery, the preferred route is directly into the stroke site (Jin et al., 2005; Bliss et al., 2010) . The infarct provides a convenient space for delivery of a relatively large volume of cells, avoiding damage to nearby intact tissue while also localizing cells to the potentially salvageable tissue in the peri-infarct (Zhong et al., 2010; Willing and Shahaduzzaman, 2013; Ballios et al., 2015) . Smith et al. compared cell transplantation to the intracerebroventricular or intraparenchymal peri-infarct locations and after 14 weeks only found surviving cells when delivered into the intraparenchymal peri-infarct (Smith et al., 2012) . However, the advantages of injection into the infarct also come with obstacles: there is a lack of ECM and vasculature to retain cells at the site of injection and support survival, the presence of proapoptotic signals from surrounding cells, and immune cell infiltration (Modo et al., 2002; Kelly et al., 2004; Hicks et al., 2009) . Biomaterials can provide a scaffold to fill the stroke cavity, providing a substrate for cell adhesion and aiding in cell distribution and retention at the injection site to prevent washout into the CSF.
Cell retention immediately after injection into the brain is important for long-term cell survival and functional recovery. If injected in a saline solution, cells can backflow out of the brain tissue through the needle tract made by the injection (Ballios et al., 2015) . A hydrogel system that can gel in situ is ideal as it provides an injectable material that becomes more viscous once in the brain and retains cells at the infarct site. Studies directly comparing cell transplantation with and without a hydrogel carrier have reported a higher number of cells in the brain immediately following injection with the use of a hydrogel (Ballios et al., 2015; Cai et al., 2015) , which is attributed to increased cell retention. HAMC, which is shear-thinning and inverse-thermal gelling, allows cells to be injected through a fine-gage needle into the brain where it will gel to localize cells to the injury site (Ballios et al., 2015; Payne et al., 2017) . HAMC provides superior cell distribution and larger maximal depth in the infarct area, which correlates to improved functional recovery compared to saline (Ballios et al., 2015) . In a different approach, Cai et al. developed a dual crosslinking hydrogel system, termed SHIELD, composed of a star-PEG copolymer and a recombinant peptide sequence (Cai et al., 2015) . The components of SHIELD form a weak physical network prior to delivery in order to protect cells as they pass through the syringe, then undergoes a second crosslinking in situ by thermal phase transition of the recombinant protein to increase the percentage of cells retained postinjection. While only tested with adipose-derived stem cells transplanted subcutaneously, this biomaterial system may enhance cell survival and retention in other tissues.
Cell Survival
Transplantation of cells directly into the stroke cavity often leads to widespread cell death, attributable in part to anoikis (i.e., lack of adhesion cues) (Jen et al., 1996; Hersel et al., 2003) . The addition of ECM components to a cell delivery vehicle can mimic the native ECM, providing adhesion cues to transplanted cells and increasing the success of transplantation. An alternative to full-length protein immobilization is the use of short synthetic peptide sequences, which are advantageous because they are more stable than proteins and thus less susceptible to degradation, are easier and less costly to synthesize, and can target one particular molecular pathway in the cell, unlike proteins that often have different functional domains that may elicit unwanted responses (Hersel et al., 2003; Cooke et al., 2010) . NSCs express many integrins that allow them to interact with ECM proteins, such as β1-integrin, which binds to the IKVAV sequence of laminin and promotes neuronal differentiation (Pan et al., 2014) . During development many integrins are expressed on NSCs in a temporal fashion as they differentiate, which should be taken into account when designing a hydrogel with adhesion molecules (Milner and Campbell, 2002; Wojcik-Stanaszek et al., 2011) . The developmental stage from which NSCs are derived can also determine which integrins are expressed, affecting the binding ability of cells to ECM ligands. For example, of mouse NSPCs derived from embryonic, early postnatal or adult SVZ, only postnatal-derived NSPCs adhered to a collagen I hydrogel (Bergström et al., 2014) .
Notwithstanding other common adhesive ligands, laminin and the laminin-derived peptide IKVAV have been used successfully for cell delivery to the brain (Stabenfeldt et al., 2006; Cheng et al., 2013; Somaa et al., 2017) . NPCs express the major integrin for laminin, α6β1, which promotes differentiation of hESCs to neurons in vitro (Ma et al., 2008; Stabenfeldt et al., 2010) . When collagen I hydrogels containing fibronectin or laminin were compared for delivery of fetal-derived NSCs, laminin-containing gels resulted in increased cell survival 8 weeks posttransplantation compared to those with fibronectin (Tate et al., 2009 ). The authors do not offer a mechanism for the superior performance of laminin over fibronectin, but laminin may promote neuronal differentiation and neurite extension (Ma et al., 2008; . Another study which used a self-assembling peptide (SAP) hydrogel of repeating RADA amino acid units with IKVAV enhanced survival of rat NSCs in vitro compared to an SAP hydrogel without IKVAV, and improved survival of NSCs and expression of neuronal markers 6 weeks after transplantation into a rat TBI model (Cheng et al., 2013) . Using a similar SAP IKVAV hydrogel, human NPCs transplanted into a rat stroke model reduced brain atrophy and improved recovery of motor function up to 9 months posttransplantation while enhancing neuronal differentiation (Somaa et al., 2017) (Figure 4) .
Promoting Cell Differentiation and integration
Once cells are delivered to the site of injury, they must not only survive long enough to be therapeutically efficacious, but also differentiate and integrate into the host tissue to promote sustained functional recovery. It has been reported that when undifferentiated NSCs are transplanted into the stroke-injured brain, they often differentiate into astrocytes over neurons (Dziewczapolski et al., 2003; Abeysinghe et al., 2015; Ballios et al., 2015) , which may contribute to the glial scar. Therefore, if the goal is neuronal replacement, it is desirable to control the cell fate after injection with the delivery system.
The properties of the biomaterial alone can influence neural cell fate. For example, ventral midbrain-derived NPCs will differentiate into neurons when the mechanical properties of an HA hydrogel match that of the neonatal brain (Seidlits et al., 2010) . Proliferation of NSCs can be controlled by changing the modulus of 3D alginate hydrogels, with stiffer gels causing a reduction in proliferation and βIII-tubulin expression (Banerjee et al., 2009 ). The differentiation of cells cultured on fibrous scaffolds can be controlled by tuning the thickness of the fibers; rat NSCs cultured on polyethersulfone fiber meshes differentiate preferentially into oligodendrocytes on smaller diameter fibers and into neurons on wider diameter fibers (Christopherson et al., 2009) . Others have seen an increase in NSC differentiation in vivo with the use of HA hydrogels (Lam et al., 2014; Führmann et al., 2016; Moshayedi et al., 2016) .
Differentiation of Transplanted Cells
In addition to acting as a physical scaffold, biomaterials can be combined with factors to help promote the integration of transplanted cells by guiding axon growth and synapse formation, and/or stimulating the differentiation of delivered cells into the desired phenotype. As biomaterials allow the controlled release of factors for sustained availability to transplanted cells, they can be used to deliver cells concurrently with factors to both support initial survival of cells and promote later differentiation. Many factors can control cell fate, yet few have been tested in combination with cell delivery in a hydrogel delivery system for stroke. Moshayedi et al. (2016) encapsulated hiPSC-derived NPCs in HA gels modified with MMP-cleavable sequences for degradation in the brain, as well as soluble factors, BDNF and BMP4, and adhesive laminin peptides, YIGSR and IKVAV (Moshayedi et al., 2016) . The authors found that after injection of the hydrogel with cells into the stroke-injured mouse brain, BDNF and BMP4 promoted astrocytic differentiation whereas the laminin sequences promoted neuronal differentiation. Other studies have used synthetic microparticles to release growth factors in conjunction with cell delivery, albeit with mixed results. One study used PLGA microparticles coated with laminin and containing encapsulated VEGF to deliver MSCs that were adhered to the particle surface (Quittet et al., 2015) . The authors reported that MSC transdifferentiated into neurons due to the presence of laminin, recruited blood vessels to the site, and increased the number of endogenous DCX-positive cells in the infarct. Despite the beneficial tissue effects, the authors did not report functional recovery in a battery of behavioral tests and suggested that this could have been the result of an unanticipated delay in VEGF release in vivo, such that an insufficient amount of VEGF was released during the therapeutic window. Another study combined BDNF-releasing PLGA microparticles, coated with fibronectin, seeded with MSC-like cells on the surface, and all blended into a silanized-hydroxypropyl MC hydrogel (Kandalam et al., 2017) . The authors found that this combination promoted neural differentiation of the cells as well as upregulated the secretion of beneficial growth factors and chemokines, but did not test cell viability. A study which implanted VEGF-releasing PLGA microparticles with human NSCs into the brain saw neovascularization within the infarct site, but also a large amount of immune cell infiltration and decreased transplanted cell viability over time (Bible et al., 2012) . The authors suggested that the increased cell death may have been a result of the degradation of the PLGA into acidic byproducts. Indeed, a significantly higher concentration of PLGA was used in their formulation compared to the previously described studies, as well as a different cell type (NSC vs. MSC), suggesting that the concentration of PLGA requires optimization for cell viability. Although multicomponent strategies such as these can target multiple repair pathways, it remains a challenge to gain mechanistic insight into recovery without the many required controls. In many cases, although the effect of a factor alone is known, the synergistic interactions between two or more factors are not. Further work needs to be done to identify promising combinations to augment cell delivery while elucidating the mechanism behind recovery.
Axon Guidance and Synapse Formation
The ability of delivered cells to form connections with the host neurons, functionally integrating into the established circuitry, is a crucial step for successful cell replacement therapy (Ishibashi et al., 2004; Tornero et al., 2017) . Without the appropriate stimuli, such as topographical or chemical cues, transplanted cells may not form these functional connections. Biomaterials have been used extensively to provide topographical cues to cells in vitro and in spinal cord injury models, but this is a newly emerging strategy for in vivo stroke models (Béduer et al., 2012; Nih et al., 2016; Tarus et al., 2016) . A pioneering study engineered a micropatterned solid polydimethylsilosane (PDMS) scaffold containing microchannels and seeded with neurons for implantation into the rat brain. The authors reported significant motor recovery and increased cell survival 3 weeks after implantation compared to the sham animals (Vaysse et al., 2015) . In a follow-up publication, the host response to the scaffold was analyzed: there was no significant increase in activated ED1-positive microglia at the implant site and surprisingly a decrease in the astrogliosis response compared to the sham (Davoust et al., 2017) , suggesting that the implant is well tolerated long-term. Future studies could also focus on combining topographical cues with some of the factors discussed in previous sections known to promote connectivity and plasticity in the brain (Wei et al., 2007; Bliss et al., 2010) .
OUTLOOK improving Biomaterial Design
Biomaterials have been successfully used as delivery vehicles for drug and cell therapeutics to the brain. Many of the materials discussed meet necessary design criteria (biocompatibility, minimally swelling, injectable, shape adaptable, and biodegradable/ bioresorbable). However, there has been limited exploration of the material itself as a therapeutic. Advances in material design that have been implemented in other tissue systems, such as modifications to material porosity, topography and mechanical cues to control the cellular response to the biomaterial, can be adapted for brain repair. Only recently has porosity been explored in the context of brain repair; a micro-porous HA hydrogel, injected into the stroke cavity, demonstrated that porosity can be used to achieve superior cellular infiltration and attenuation of the inflammatory response compared to non-porous hydrogels (Nih et al., 2017) . Future work may include optimizing the pore size of a material for the desired cellular response, such as for neurogenesis, axonogenesis or vasculogenesis. In addition, surface functionalization, such as peptide modification, can be combined with a porous hydrogel to mimic cell-cell interactions at the biomaterial-cell interface, which has been demonstrated to control stem cell differentiation (Stabenfeldt et al., 2006; Tate et al., 2009; . While the mechanical and chemical properties of a biomaterial are typically linked, new synthetic strategies will allow the ECM ligand concentration to be decoupled from the hydrogel crosslink density, thereby resulting in materials with independently tunable mechanical and chemical properties (Fisher et al., 2015) . Computational advancements and machine learning will allow us to use predictive modeling to explore and optimize multiple biomaterial parameters (e.g., elasticity, porosity, composition) simultaneously, enabling improvements in existing materials and the development of novel materials (Vasilevich et al., 2017) .
Biomaterials in Novel Treatments
Biomaterials will enable sustained delivery of novel treatments. The direct reprogramming of astrocytes in the glial scar into proliferative neuroblasts has been proposed as a feasible method of reducing the glial scar, and generating neuron and oligodendrocyte precursors at the site of injury and repair, even in aged brains (Niu et al., 2013; Guo et al., 2014b) . This can be achieved through retroviral or lentiviral transfection of GFAP + astrocytes to express reprogramming factors NeuroD1 or Sox2. However, low transfection efficiency and concerns of diffuse non-specific targeting hinder this approach (Li et al., 2016) . Biomaterials can be used to address these concerns by sequestering viral particles, increasing local concentrations of the vector and extending the length of virus activity to increase transfection efficiency of infiltrating cells. Retaining the viral particles within the gel limits transfection to cells at the boundary and to infiltrating cells, controlling reprogramming to cells solely within the glial scar-bounded infarct and reducing diffuse non-specific exposure (Shin and Shea, 2010; Seidlits et al., 2013) . Recent developments have found that cocktails of small molecules can achieve the same reprogramming as viral vectors, without xenobiotic concerns, in astroglial cells (Zhang et al., 2015) and fibroblasts (Hu et al., 2015; Li et al., 2015) . Indeed, a few innovative researchers have begun incorporating these factors into nanoparticles to reprogram astrocytes into neurons and oligodendrocytes (Li et al., 2016 (Li et al., , 2017 . Many of the discussed advancements in local delivery of therapeutic factors are directly applicable to local and controlled delivery of reprogramming molecules.
The ability of neurons to be stimulated by electrical fields has been explored as a novel strategy to promote both cell migration and differentiation. Stimulating cell migration takes advantage of the galvanotaxis demonstrated by NSPCs (Babona-Pilipos et al., 2011) , whereby neurons migrate in response to an applied electric field. This approach has been proposed for in vivo use through externally applied electric fields to increase and direct the migration of endogenous NSPCs, though it could also be used to direct the migration of transplanted stem cells to prevent their clustering (Iwasa et al., 2017) . Recent advances in electrically conductive materials may aid in scaling this approach to larger human brains where sufficient electrical fields may be difficult to generate or more spatially defined electrical fields may be desired (Zhou et al., 2017) .
In addition to influencing cell migration, electrical stimulation of ESCs can bias their fate toward neuronal differentiation via changes in calcium influx (Yamada et al., 2007; Pires et al., 2015) . Graphene is a biocompatible material with good electrical conductivity that allows electrical cues to be introduced to the cells to promote differentiation and connectivity (Gardin et al., 2016) . Various forms of graphene can be used for neural cell culture, increasing differentiation of NSCs into neurons or oligodendrocytes (Menaa et al., 2015) , and it can be utilized to differentiate cells in vitro prior to transplantation (Heo et al., 2011 ). An interesting study combined graphene in the form of single-walled carbon nanotubes with laminin to culture NSCs, which were then stimulated by an electrical current, generating action potentials and forming a neural network (Chao et al., 2009) . Graphene has shown promise in vitro but the in vivo biocompatibility and tolerance remains unknown. Implantation of electrically preconditioned cells was recently demonstrated using a conductive polymer scaffold where Human neural progenitor cells (hNPCs) cultured on a polypyrrole scaffold and exposed to electrical stimulation upregulated genes in the VEGF-A pathway (George et al., 2017) . When cells on these scaffolds were stimulated and transplanted onto the cortical surface of stroke-injured rats they elicited functional improvement in multiple behavioral tasks and increased the peri-infarct vasculature in a VEGF-dependent manner compared to unconditioned cells; however, no surviving cells were detected at two weeks posttransplantation. Future work combining electrical stimulation and cell delivery may lead to further advances in the in vivo control of stem cell fate.
improving Clinical Translation
Advances in biomaterials and tissue engineering improve therapies that aim to protect and repair the brain, serving as vehicles for drug and cell delivery, and scaffolds for tissue regeneration that integrate with the host tissue. However, it remains a nascent field and successful clinical translation will require learning from the failures of previous neuroprotective efforts (O'Collins et al., 2006) . Many preclinical studies with biomaterials have demonstrated a limited number of tissue-specific outcomes without providing evidence for behavioral recovery. Though the lack of behavioral recovery does not undermine the value of a study, landmark studies will require robust demonstration of functional outcomes in multiple tests. Another major hurdle is the lack of a consistent set of clinically relevant goals and study designs. Most preclinical studies limit testing to a single stroke model in young animals with homogeneous etiologies, yet the majority of clinical cases occur in an older population with heterogeneous etiologies (Savitz et al., 2011) . Thus, conclusions drawn from preclinical studies using a single model may not be robust enough for the heterogeneous etiologies seen clinically, and studies exclusively on young animals are not reflective of the stroke demographic.
As one set of studies demonstrated, aged animals have a lessrobust capacity for plasticity and require modifications to their treatment to achieve the same outcome found in young animals (Clarkson et al., 2015) . Future studies should also incorporate the guidelines set forward by Stroke Therapy Academic Industry Round Table (STAiRS) for preclinical studies in order to build a knowledge base for the field that has practical translation aspects [Stroke Therapy Academic Industry Roundtable (STAIR), 1999; Saver et al., 2009] . Along with appropriate study design, the choice of biomaterial and any chemical modifications should be carefully considered. In addition to the basic requirements discussed herein, the biomaterial must be easily sterilized and manufactured, and any chemistry involved in manufacturing the material should be reproducible, scalable and cost-effective.
Biomaterial delivery can be improved by combining it with in vivo imaging. One often overlooked fact is that while human strokes vary in their size and location, preclinical studies often assume a fixed infarct volume and use a fixed volume of hydrogel. To address this, the Modo group used magnetic resonance imaging (MRI) to measure the individual infarct volume in each animal, in order to adjust the volume of hydrogel delivered and to guide injections to the precise site of injury (Massensini et al., 2015) . The group also employed a drainage catheter to remove any fluid buildup in the cavity, displacing it for the injected hydrogel to provide better hydrogel retention and reduce backflow. MRI can also be used to track the biomaterial implant over time, ensuring accurate material implantation, sufficient stability, and adequate degradation for newly formed tissue (Cook et al., 2017) . These strategies can improve the delivery and tracking of biomaterials in the brain, increasing both the success of the treatment and its relevance to clinical applications.
Brain repair is a multifaceted process; achieving functional repair with biomaterial-based therapies may require combination with other treatment modalities, such as rehabilitation or transcranial magnetic stimulation (TMS), in order to target multiple repair pathways (Wieloch and Nikolich, 2006) . Regenerated or reestablished neural circuitry, if not directed by an appropriate stimulus, can result in uncontrolled plasticity and/or aberrant connections (Murphy and Corbett, 2009) . Rehabilitation may enhance functional integration and wiring of newly generated or transplanted neurons (Winstein et al., 2016) . Targeting the desired neural pathways with specific rehabilitative tasks simultaneously with delivered cells or drugs may stimulate the reestablishment of appropriate functional connections and discourage the formation of aberrant ones; this was demonstrated with the use of ChABC to produce task-specific recovery (Soleman et al., 2012) . Furthermore, recovery of fine motor skills appears to be dependent on receiving the proper type of training; animals that received training in gross locomotor skills performed worse in fine motor tasks than those which received no treatment (García-Alías et al., 2009) . Thus, functional outcomes with reparative therapies may require appropriate rehabilitation to guide plasticity and rewiring. The reduced plasticity exhibited in chronic injuries and aged patients may make functional integration difficult, even if combined with rehabilitation. Direct brain stimulation with TMS has been used to stimulate brain regions for stroke recovery (Takeuchi et al., 2005; Khedr et al., 2010) and enhance BDNF-mediated plasticity (Wang et al., 2011a) . TMS has also been shown to increase the proliferation of resident adult NSCs in the SVZ though the miR-25/p57 pathway (Guo et al., 2014a) . While TMS may be combined with delivery of cells or stimulation of endogenous cells, research has shown that the intensity of TMS must be finely tuned or it can negatively impact cell survival (Beom et al., 2015; Kremer et al., 2016) , suggesting that more work needs to be done before this strategy can be combined successfully. Nonetheless, using a combinatorial therapy of biomaterials, drug and/or cells, and rehabilitation or TMS, may provide the synergistic approach required to achieve recovery in chronic injuries and aged patients.
Conclusion
Stroke is a devastating event that manifests as a complex, multicellular injury with limited ability for self-repair. By combining drug and cell delivery strategies with biomaterial solutions, we can enhance the efficacy of treatments to promote regeneration. Although the architecture and morphology of the brain impose a unique set of constraints on biomaterial design, innovative research provides superior drug and cell delivery to the brain with a wide-range of materials, from controlled release of multiple drugs to promote endogenous regeneration, to increased survival and differentiation of delivered cells. While the field has enjoyed preclinical success, several hurdles must be overcome for clinical translation. Some of these can be addressed with the use of consistent guidelines for material design, as well as methodological improvements to the delivery of the biomaterial. The use of a combinatorial strategycombining the delivery with cells or other factors, or drugs/cells with other interventions such as rehabilitation-may provide the multipronged approach needed for regeneration and recovery. Previously failed preclinical strategies may be resurrected through combination with biomaterials, especially if the reason for failure was off-target effects or inability to cross the BBB. Future biomaterial development should be tailored to advancements in preclinical and clinical knowledge of stroke repair treatment modalities.
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